Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study

Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study

Corrado Pelaia,1 Anna Ferrante Bannera,1 Fioramante Lello Rotundo,1 Francesco Giuseppe Tropea,1 Giuseppe Armentaro,2 Angelantonio Maglio,3 Angela Sciacqua,2 Alessandro Vatrella,3 Girolamo Pelaia1 1Department of Health Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 2Department of...

Full description

Bibliographic Details
Main Authors:	Pelaia C, Ferrante Bannera A, Rotundo FL, Tropea FG, Armentaro G, Maglio A, Sciacqua A, Vatrella A, Pelaia G
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-05-01
Series:	International Journal of COPD
Subjects:	copd dual inhaled therapy lung function airway resistance exacerbations.
Online Access:	https://www.dovepress.com/clinical-and-functional-effects-of-inhaled-dual-therapy-umeclidiniumvi-peer-reviewed-fulltext-article-COPD

Similar Items

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01)

Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
by: Panettieri Jr RA, et al.
Published: (2022-09-01)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
by: Singh D, et al.
Published: (2016-06-01)

Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease
by: Sun Hye Shin, et al.
Published: (2022-05-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
by: Requena G, et al.
Published: (2023-09-01)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
by: Sicras Mainar A, et al.
Published: (2019-09-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)

Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey
by: Miravitlles M, et al.
Published: (2022-07-01)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
by: Kalhan R, et al.
Published: (2021-04-01)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
by: François Maltais, et al.
Published: (2019-10-01)

Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction
by: Hyo Jin Lee, et al.
Published: (2024-01-01)

Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study
by: Ferguson GT, et al.
Published: (2020-11-01)

COPD Patients’ Behaviour When Involved in the Choice of Inhaler Device
by: Sorin Bivolaru, et al.
Published: (2023-05-01)

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models
by: Ami R. Buikema, et al.
Published: (2018-10-01)

COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
by: Hanania NA, et al.
Published: (2023-03-01)

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
by: Neches García V, et al.
Published: (2022-09-01)

Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States
by: Bogart M, et al.
Published: (2024-01-01)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
by: Vestbo J, et al.
Published: (2019-04-01)

Critical Inhaler Handling Error Is an Independent Risk Factor for Frequent Exacerbations of Chronic Obstructive Pulmonary Disease: Interim Results of a Single Center Prospective Study
by: Ahn JH, et al.
Published: (2019-12-01)

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
by: Bogart M, et al.
Published: (2023-12-01)

Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice
by: Cataldo D, et al.
Published: (2018-07-01)

Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle
by: Shaikh N, et al.
Published: (2017-06-01)

“Breathing New Life Into Chronic Obstructive Pulmonary Disease (COPD)” – Results From An Online Survey Of UK Patients
by: Titmarsh S, et al.
Published: (2019-12-01)

The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study
by: Qing Song, et al.
Published: (2023-12-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)

Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain
by: Trigueros JA, et al.
Published: (2022-11-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
by: Czira A, et al.
Published: (2023-04-01)

Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study
by: Janwillem Kocks, et al.
Published: (2023-08-01)

The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD
by: Russell REK, et al.
Published: (2019-05-01)

Decline of COPD exacerbations in clinical trials over two decades – a systematic review and meta-regression
by: Stefan Andreas, et al.
Published: (2019-08-01)

High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis
by: Archontakis Barakakis P, et al.
Published: (2023-04-01)

Characterization of COPD Admissions During the First COVID-19 Outbreak
by: Cosio BG, et al.
Published: (2021-06-01)

Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China
by: Lan Y, et al.
Published: (2022-03-01)

Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China
by: Ling Lin, et al.
Published: (2023-03-01)

Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go?
by: Faisal A AI-Kassimi, et al.
Published: (2013-01-01)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
by: Avdeev S, et al.
Published: (2019-06-01)

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
by: Sethi S, et al.
Published: (2023-04-01)

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial
by: Beeh KM, et al.
Published: (2024-01-01)